The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

NCT02085265 Phase 2 TERMINATED

To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker (ARB) compared to an angiotensin converting enzyme inhibitor (ACEI).

Details

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	Phase 2
Status	TERMINATED
Enrolment	23
Start date	2014-03
Completion	2025-02-28

Conditions

• Alzheimer's Disease

Interventions

• Perindopril
• Telmisartan

Primary outcomes

• Ventricular enlargement — 12 months
  Change in ventricular size, on 3D T1 MR imaging, after 12 months of treatment
• Safety - Blood pressure — 12 months
  Change in blood pressure (BP) measurements after 12 months of treatment.
• Safety - Vital signs — 12 months
  Change in vital sign (heart rate, pulse) measurements after 12 months of treatment.
• Safety - Electrolytes — 12 months
  Change in electrolyte measurements (Na, K) after 12 months of treatment.
• Safety - Adverse Events — 12 months
  Adverse events and serious adverse events over 12 months of treatment.

Countries

Canada